NFL Biosciences SAS (ALNFL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NFL Biosciences SAS (ALNFL) has a cash flow conversion efficiency ratio of 0.030x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€57.51K ≈ $67.24K USD) by net assets (€1.91 Million ≈ $2.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NFL Biosciences SAS (ALNFL) liquidity interval to measure how many days the company can operate on defensive assets alone.
NFL Biosciences SAS - Cash Flow Conversion Efficiency Trend (2020–2022)
This chart illustrates how NFL Biosciences SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NFL Biosciences SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NFL Biosciences SAS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seamless Distribution Systems AB
ST:SDS
|
-0.126x |
|
Lepidico Ltd
AU:LPD
|
0.000x |
|
Photonike Capital SA
PA:MLPHO
|
N/A |
|
eEducation Albert AB
ST:ALBERT
|
0.534x |
|
Jackpot Digital Inc
V:JJ
|
0.117x |
|
PZ Cormay SA
WAR:CRM
|
-0.019x |
|
CSH Alliance Bhd
KLSE:7165
|
-0.263x |
|
UCrest Bhd
KLSE:0005
|
0.030x |
Annual Cash Flow Conversion Efficiency for NFL Biosciences SAS (2020–2022)
The table below shows the annual cash flow conversion efficiency of NFL Biosciences SAS from 2020 to 2022. For the full company profile with market capitalisation and key ratios, see ALNFL market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €844.00K ≈ $986.72K |
€104.89K ≈ $122.63K |
0.124x | +369.60% |
| 2021-12-31 | €3.29 Million ≈ $3.84 Million |
€87.00K ≈ $101.71K |
0.026x | -95.27% |
| 2020-12-31 | €150.03K ≈ $175.39K |
€83.91K ≈ $98.10K |
0.559x | -- |
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding… Read more